A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Autoren

  • A. Lange
  • A. Prenzler
  • M. Frank
  • M. Kirstein
  • A. Vogel
  • J. M. Von Der Schulenburg

Externe Organisationen

  • Medizinische Hochschule Hannover (MHH)
Forschungs-netzwerk anzeigen

Details

OriginalspracheEnglisch
Seiten (von - bis)40-49
Seitenumfang10
FachzeitschriftEuropean Journal of Cancer
Jahrgang50
Ausgabenummer1
Frühes Online-Datum4 Sept. 2013
PublikationsstatusVeröffentlicht - Jan. 2014

Abstract

Metastatic colorectal cancer (mCRC) imposes a substantial health burden on patients and society. In recent years, advances in the treatment of mCRC have mainly resulted from the introduction of monoclonal antibodies (MoAbs). However, the application of these MoAbs considerably increases treatment costs. The objective of this article is to review and assess the economic evidence of MoAB treatment in mCRC. A systematic literature review was conducted and cost-effectiveness (CE) as well as cost-utility-studies were identified. For this, Medline, Embase, SciSearch, Cochrane, and nine other databases were searched from 2000 through February 2013 for full-text publications. The quality of the studies was assessed via a validated assessment tool (Quality of Health Economic Studies (QHES)). A total of 843 publications were screened. Of those, 15 studies involving the MoAbs bevacizumab, cetuximab and panitumumab met all inclusion criteria. Four studies analysed the CE of first-line treatment with bevacizumab and nine the CE of cetuximab in subsequent treatment lines. Two studies dealt with the CE of panitumumab. The analysis of sequential regimes and the direct comparison of two MoABs were analysed by only one study each. The quality of the included studies was high with the exception of one study. Conclusions The treatment with bevacizumab, cetuximab and panitumumab is mainly considered to be not cost-effective in patients with mCRC. However, testing for Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or panitumumab is found to be clearly cost-effective compared to no testing. Future research should focus on the CE of first-line treatment with cetuximab or panitumumab and studies on upcoming agents like regorafenib and aflibercept.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. / Lange, A.; Prenzler, A.; Frank, M. et al.
in: European Journal of Cancer, Jahrgang 50, Nr. 1, 01.2014, S. 40-49.

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Lange, A, Prenzler, A, Frank, M, Kirstein, M, Vogel, A & Von Der Schulenburg, JM 2014, 'A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer', European Journal of Cancer, Jg. 50, Nr. 1, S. 40-49. https://doi.org/10.1016/j.ejca.2013.08.008
Lange, A., Prenzler, A., Frank, M., Kirstein, M., Vogel, A., & Von Der Schulenburg, J. M. (2014). A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European Journal of Cancer, 50(1), 40-49. https://doi.org/10.1016/j.ejca.2013.08.008
Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, Von Der Schulenburg JM. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European Journal of Cancer. 2014 Jan;50(1):40-49. Epub 2013 Sep 4. doi: 10.1016/j.ejca.2013.08.008
Lange, A. ; Prenzler, A. ; Frank, M. et al. / A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. in: European Journal of Cancer. 2014 ; Jahrgang 50, Nr. 1. S. 40-49.
Download
@article{488075cf1a3d4a72b4e3f31788308552,
title = "A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer",
abstract = "Metastatic colorectal cancer (mCRC) imposes a substantial health burden on patients and society. In recent years, advances in the treatment of mCRC have mainly resulted from the introduction of monoclonal antibodies (MoAbs). However, the application of these MoAbs considerably increases treatment costs. The objective of this article is to review and assess the economic evidence of MoAB treatment in mCRC. A systematic literature review was conducted and cost-effectiveness (CE) as well as cost-utility-studies were identified. For this, Medline, Embase, SciSearch, Cochrane, and nine other databases were searched from 2000 through February 2013 for full-text publications. The quality of the studies was assessed via a validated assessment tool (Quality of Health Economic Studies (QHES)). A total of 843 publications were screened. Of those, 15 studies involving the MoAbs bevacizumab, cetuximab and panitumumab met all inclusion criteria. Four studies analysed the CE of first-line treatment with bevacizumab and nine the CE of cetuximab in subsequent treatment lines. Two studies dealt with the CE of panitumumab. The analysis of sequential regimes and the direct comparison of two MoABs were analysed by only one study each. The quality of the included studies was high with the exception of one study. Conclusions The treatment with bevacizumab, cetuximab and panitumumab is mainly considered to be not cost-effective in patients with mCRC. However, testing for Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or panitumumab is found to be clearly cost-effective compared to no testing. Future research should focus on the CE of first-line treatment with cetuximab or panitumumab and studies on upcoming agents like regorafenib and aflibercept.",
keywords = "Advanced colorectal cancer, Bevacizumab, Cetuximab, Cost-effectiveness analysis, Cost-utility analysis, Health economics, Metastatic colorectal cancer, Monoclonal antibody, Panitumumab, Targeted therapy",
author = "A. Lange and A. Prenzler and M. Frank and M. Kirstein and A. Vogel and {Von Der Schulenburg}, {J. M.}",
note = "Funding Information: The study was funded by the German Federal Ministry of Education and Research (BMBF). ",
year = "2014",
month = jan,
doi = "10.1016/j.ejca.2013.08.008",
language = "English",
volume = "50",
pages = "40--49",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd.",
number = "1",

}

Download

TY - JOUR

T1 - A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

AU - Lange, A.

AU - Prenzler, A.

AU - Frank, M.

AU - Kirstein, M.

AU - Vogel, A.

AU - Von Der Schulenburg, J. M.

N1 - Funding Information: The study was funded by the German Federal Ministry of Education and Research (BMBF).

PY - 2014/1

Y1 - 2014/1

N2 - Metastatic colorectal cancer (mCRC) imposes a substantial health burden on patients and society. In recent years, advances in the treatment of mCRC have mainly resulted from the introduction of monoclonal antibodies (MoAbs). However, the application of these MoAbs considerably increases treatment costs. The objective of this article is to review and assess the economic evidence of MoAB treatment in mCRC. A systematic literature review was conducted and cost-effectiveness (CE) as well as cost-utility-studies were identified. For this, Medline, Embase, SciSearch, Cochrane, and nine other databases were searched from 2000 through February 2013 for full-text publications. The quality of the studies was assessed via a validated assessment tool (Quality of Health Economic Studies (QHES)). A total of 843 publications were screened. Of those, 15 studies involving the MoAbs bevacizumab, cetuximab and panitumumab met all inclusion criteria. Four studies analysed the CE of first-line treatment with bevacizumab and nine the CE of cetuximab in subsequent treatment lines. Two studies dealt with the CE of panitumumab. The analysis of sequential regimes and the direct comparison of two MoABs were analysed by only one study each. The quality of the included studies was high with the exception of one study. Conclusions The treatment with bevacizumab, cetuximab and panitumumab is mainly considered to be not cost-effective in patients with mCRC. However, testing for Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or panitumumab is found to be clearly cost-effective compared to no testing. Future research should focus on the CE of first-line treatment with cetuximab or panitumumab and studies on upcoming agents like regorafenib and aflibercept.

AB - Metastatic colorectal cancer (mCRC) imposes a substantial health burden on patients and society. In recent years, advances in the treatment of mCRC have mainly resulted from the introduction of monoclonal antibodies (MoAbs). However, the application of these MoAbs considerably increases treatment costs. The objective of this article is to review and assess the economic evidence of MoAB treatment in mCRC. A systematic literature review was conducted and cost-effectiveness (CE) as well as cost-utility-studies were identified. For this, Medline, Embase, SciSearch, Cochrane, and nine other databases were searched from 2000 through February 2013 for full-text publications. The quality of the studies was assessed via a validated assessment tool (Quality of Health Economic Studies (QHES)). A total of 843 publications were screened. Of those, 15 studies involving the MoAbs bevacizumab, cetuximab and panitumumab met all inclusion criteria. Four studies analysed the CE of first-line treatment with bevacizumab and nine the CE of cetuximab in subsequent treatment lines. Two studies dealt with the CE of panitumumab. The analysis of sequential regimes and the direct comparison of two MoABs were analysed by only one study each. The quality of the included studies was high with the exception of one study. Conclusions The treatment with bevacizumab, cetuximab and panitumumab is mainly considered to be not cost-effective in patients with mCRC. However, testing for Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or panitumumab is found to be clearly cost-effective compared to no testing. Future research should focus on the CE of first-line treatment with cetuximab or panitumumab and studies on upcoming agents like regorafenib and aflibercept.

KW - Advanced colorectal cancer

KW - Bevacizumab

KW - Cetuximab

KW - Cost-effectiveness analysis

KW - Cost-utility analysis

KW - Health economics

KW - Metastatic colorectal cancer

KW - Monoclonal antibody

KW - Panitumumab

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84891634642&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.08.008

DO - 10.1016/j.ejca.2013.08.008

M3 - Review article

C2 - 24011538

AN - SCOPUS:84891634642

VL - 50

SP - 40

EP - 49

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -